BAG3 is a multifunctional co‐chaperone that plays a central role in maintaining protein quality control by regulating the activity of heat shock proteins, particularly Hsp70. Its versatile ...
Myofibrillar myopathy type 6 (MFM6) is a rare genetic muscle disorder that leads to severe muscle weakness and a drastically ...
Myofibrillar myopathy type 6 (MFM6) is a rare genetic muscle disorder that leads to severe muscle weakness and a drastically shortened life expectancy due to a disruption in muscle protein regulation.
Myofibrillar myopathy type 6 (MFM6) is a rare genetic muscle disorder that leads to severe muscle weakness and a drastically ...
WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies ...
Affinia Therapeutics ("Affinia"), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class ...
WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies ...
Researchers at the University Hospital Bonn have developed a humanized mouse model for myofibrillar myopathy type 6 (MFM6), revealing that impaired autophagy driven by a defective BAG3 protein leads ...
BAG3 DCM is a devastating monogenic heart disease affecting more than 70,000 patients in the U.S., Europe, and U.K., with almost 25% of patients requiring a heart transplant AFTX-201 is a potential ...
An investigational medicine that addresses the genetic root cause of BAG3 DCM, AFTX-201 is being evaluated in the UPBEAT © clinical trial AFTX-201 is designed using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results